2005至2014年德国胸腹主动脉瘤开放与腔内手术的住院发生率、治疗及院内死亡率
基于德国DRG微数据,分析2005至2014年2607例胸腹主动脉瘤手术病例,其中f/bEVAR占32.8%,开放修复占54.5%,杂交占13.6%。院内死亡率破裂型为46.1%,非破裂型为15.9%;f/bEVAR(RR 0.35)和高医院容量与死亡率降低相关,破裂、年龄和合并症与死亡率升高相关。
要点
- 2014年非破裂胸腹主动脉瘤中76%采用腔内修复,较2005年6%显著增加。
- 破裂、年龄增长和合并症增加死亡风险,高容量医院结局更优。
核心结论
- 胸腹主动脉瘤腔内修复比例十年间大幅上升,2014年非破裂病例达76%。
- f/bEVAR和高医院容量与院内死亡率降低相关,破裂、年龄和合并症与死亡率升高相关。
研究设计与样本
- 基于德国联邦统计局DRG统计的二次数据分析,纳入2005至2014年所有胸腹主动脉瘤手术病例。
- 共纳入2607例(破裂406例,非破裂2201例),采用多水平多变量回归模型调整性别、年龄、合并症、手术方式和入院类型。
主要发现
- f/bEVAR占32.8%(856例),开放修复占54.5%(1422例),杂交占13.6%(354例)。
- 非破裂胸腹主动脉瘤腔内修复比例从2005年6%升至2014年76%。
- 院内死亡率破裂型为46.1%,非破裂型为15.9%。
关键数值与推荐
- 胸腹主动脉瘤诊断编码为ICD-10 I71.5和I71.6,手术编码包括f/bEVAR(5-38a.7x、5-38a.8x)、开放修复(5-384.4)和杂交(5-384.b/c、5-38a.a/b/8/80)。
- 最常见合并症:高血压75.2%、外周动脉疾病(含腹主动脉瘤)49.5%、其他心脏病44.6%、冠心病30.6%、肾功能衰竭28.7%。
- 治疗胸腹主动脉瘤的医院数量在9年内几乎增至三倍。
临床怎么用
- 胸腹主动脉瘤治疗应优先考虑腔内修复(f/bEVAR),尤其在高容量中心可降低院内死亡率。
- 对破裂、高龄和合并症多的患者应加强风险评估和围手术期管理。
局限性
- 基于DRG行政数据,可能存在编码偏倚和混杂因素未完全调整。
- 缺乏长期随访和患者层面临床细节,无法评估远期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hospital incidence, treatment modality, and in hospital mortality after surgery are reported for thoraco-abdominal aortic aneurysms (TAAAs) treated by endovascular or open means in Germany from 2005 to 2014. METHODS: Data were extracted from diagnosis related group statistics from the German Federal Statistical Office. All inpatient cases with a diagnosis of ruptured and non-ruptured TAAA (ICD-10 I71.5 and I71.6) and procedure codes for fenestrated or branched endovascular aortic repair (f/bEVAR 5-38a.7x and 5-38a.8x), open aortic repair (OAR 5-384.4), or hybrid procedure (5-384.b/c, 5-38a.a/b/8/80) were included. To adjust for sex, age, medical risk (Elixhauser comorbidity score), type of procedure, and type of admission, a multilevel multivariable regression model with robust error variance was applied. The primary outcome was in hospital mortality; secondary outcomes were organ complications. The relationship between annual hospital volume and outcome was analysed. RESULTS: A total of 2607 cases (406 rTAAA, 2201 nrTAAA) were included. f/bEVAR was performed in 856 cases (32.8%), OAR in 1422 cases (54.5%), and hybrid repair in 354 cases (13.6%). Endovascular repair became more frequent over time (6% in 2005 vs. 76% in 2014 for nrTAAA). Hypertension (75.2%), peripheral artery disease (including abdominal aortic aneurysm, 49.5%), other heart diseases (44.6%), coronary heart disease (30.6%), and renal failure (28.7%) were the most frequently coded comorbidities. The number of hospitals treating TAAAs almost tripled within 9 years. The in hospital mortality was 46.1% for rTAAA and 15.9% for nrTAAA. f/bEVAR (RR 0.35, 0.24-0.51) and high hospital volume (p < .001) were significantly associated with decreased in hospital mortality. Aortic rupture, increasing age, and comorbidity were significantly associated with higher mortality (RR 3.17, 2.45-4.09; 1.52, 1.32-1.76, and 1.05, 1.04-1.06). CONCLUSIONS: Seventy-six percent of all TAAAs were treated endovascularly in 2014 with increasing frequency over a decade. In hospital mortality is lower with endovascular repair and in high volume centres. Aortic rupture, age, and severe comorbidities are associated with worse outcomes.
引用
- Geisbüsch S, Kuehnl A, Salvermoser M, et al. Editor's Choice - Hospital Incidence, Treatment, and In Hospital Mortality Following Open and Endovascular Surgery for Thoraco-abdominal Aortic Aneurysms in Germany from 2005 to 2014: Secondary Data Analysis of the Nationwide German DRG Microdata. Eur J Vasc Endovasc Surg. 2019. PMID: 30745030. doi:10.1016/j.ejvs.2018.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。